Internationaler Brustkrebskongress St. Gallen 2013: Primärtherapie beim frühen Brustkrebs: Evidenz, Kontroversen, Konsens

Zusammenfassung

Alle zwei Jahre findet in St. Gallen (Schweiz) die internationale Konsensuskonferenz zur Behandlung des primären Mammakarzinoms statt. Da sich das internationale Panel in St. Gallen aus Experten unterschiedlicher Länder zusammensetzt, spiegelt der Konsensus ein internationales Meinungsbild wider. Vor diesem Hintergrund erscheint es aus deutscher Sicht sinnvoll, die Abstimmungsergebnisse für den Therapiealltag in Deutschland zu konkretisieren. Eine deutsche Arbeitsgruppe mit acht Brustkrebsexperten, von denen zwei Mitglieder des internationalen St.-Gallen-Panels sind, hat daher die Abstimmungsergebnisse der St.-Gallen-Konsensuskonferenz (2013) für den Klinikalltag in Deutschland kommentiert. Inhaltliche Schwerpunkte der diesjährigen St.-Gallen-Konferenz waren operative Fragestellungen der Brust und der Axilla, strahlentherapeutische und systemische Therapieoptionen sowie die klinische Relevanz der Tumorbiologie. Intensiv diskutiert wurde der klinische Einsatz von Multigen-Assays, inkl. ihrer Bedeutung für die individuelle Therapieentscheidung.

Abstract

The International Consensus Conference on the treatment of primary breast cancer takes place every two years in St. Gallen, Switzerland. The panel in St. Gallen is composed of international members from different countries. The consensus reflects an international expert opinion. From a German perspective, it seems thus reasonable to interpret the voting results in the light of the German guidelines, i. e. AGO-recommendations and S3-guidelines for everyday practice in Germany. Consequently, a team of eight breast cancer experts, of whom two are member of the international St. Gallen panel, commented on the voting results of the St. Gallen Consensus Conference (2013). The main topics at this year’s conference were surgical issues of the breast and axilla, radiotherapeutic and systemic treatment options, and the clinical relevance of tumour biology. The clinical utility of multi-gene assays for supporting individual treatment decisions was also intensively discussed.

Schlüsselwörter

Mammakarzinom - St. Gallen Konsensus - adjuvante Therapie - neoadjuvante Therapie - multigene Signaturen

Key words

early breast cancer - St. Gallen consensus - adjuvant therapy - neoadjuvant therapy - multigene signatures

• Literatur

• 1 www.ago-online.de
• 2 Ho AY, Gupta G, King TA et al. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 2012; 118: 4944-4952
• 3 Millar EKA, Graham PH, O'Toole SA et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009; 27: 4701-4708
• 4 Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569-575
• 5 Kuehn T, Bauerfeind IGP, Fehm T et al. Sentinel Lymph Node Biopsy Before or After Neoadjuvant Chemotherapy – Final Results from the Prospective German, multiinstitutional SENTINA-Trial. Cancer Research 2012; 72: S2–2
• 6 Boughey JC, Suman VJ, Mittendorf EA et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (TO-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial. Cancer Research 2012; 72: S2–1
• 7 Haviland JS, Agrawal R, Aird E et al. The UK START (Standardisation of Breast Radiotherapy) Trials: 10-year follow-up results. Cancer Research 2012; 72: S4–1
• 8 Gluz O, Kreipe H, Degenhardt T et al. Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial. Cancer Research 2012; 71: S4–3
• 9 Kelly CM, Bernard PS, Krishnamurthy S et al. Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX^®) and the PAM50 Breast Cancer Intrinsic Classifier^TM in Early-Stage Estrogen Receptor- Positive Breast Cancer. The Oncologist 2012; 17: 492-498
• 10 Moebus V, Jackisch C, Lueck HJ et al. Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study. J Clin Oncol 2010; 28: 2874-2880
• 11 Gnant M, Mlineritsch B, Schippinger W et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. N Engl J Med 2009; 360: 679-691
• 12 Gnant M, Mlineritsch B, Lusch-Ebengreuth GL et al. Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor-Positive Early Breast Cancer. Cancer Research 2012; 71: S1–2